BerGenBio

Selective AXL inhibitors

Header Right

Main navigation

Home  /  Pipeline

Pipeline

BerGenBio is developing a pipeline of first-in-class selective Axl kinase inhibitors for aggressive liquid and solid cancers.

  • Product/Indication
  • Discovery
  • Lead optimisation
  • Preclincal
  • Phase 1
  • Phase 2
  • Phase 3

bemcentinib

Indication: NSCLC

Combination: KEYTRUDA

Partner: Merck Inc

Phase 2 B

bemcentinib

Indication: NSCLC

Combination: TARCEVA

Phase 2 B

bemcentinib

Indication: NSCLC

Combination: docetaxel

Partner: UTSW Medical Center

Phase 2 A

bemcentinib

Indication: TNBC

Target: KEYTRUDA

Partner: Merck Inc.

Phase 2 B

bemcentinib

Indication: Melanoma

Combination: KEYTRUDA / TAFINLAR, MEKINIST

Partner: Bergen University Hospital

Phase 2 B

bemcentinib

Indication: AML

Combination: single agent / cytarabine, decitabine

Phase 2 B

BGB149

Indication: Cancer

Target: AXL

Preclincal (end) - Phase 1 A

BGB601

Indication: Cancer

Target: AXL-ADC

Preclincal (end) - Phase 1 A

Discovery

Indication: Cancer

Target: undisclosed

Lead optimization (end) - Preclincal (begin)
BerGenBio Asset
Outlicensed